NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) has received an average recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have issued ratings on the stock in the […]
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) Director Group L. P. Column purchased 34,200 shares of NGM Biopharmaceuticals stock in a transaction dated Thursday, June 2nd. The stock was bought at an average price of $13.03 per share, for a total transaction of $445,626.00. Following the completion of the transaction, the director now directly owns […]
Shares of NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) have earned an average rating of “Buy” from the seven brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among […]
Wall Street analysts forecast that NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) will report earnings of ($0.42) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for NGM Biopharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.65). NGM Biopharmaceuticals […]
Analysts expect NGM Biopharmaceuticals, Inc. (NASDAQ:NGM – Get Rating) to report $22.35 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for NGM Biopharmaceuticals’ earnings. The lowest sales estimate is $15.00 million and the highest is $29.69 million. NGM Biopharmaceuticals posted sales of $21.58 million during the same […]